Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ127812790,08
KB11291130-0,79
PKN94,7294,731,19
Msft478,92479,250,15
Nokia5,3145,3160,95
IBM309,55310,250,26
Mercedes-Benz Group AG61,1561,17-0,86
PFE25,8825,890,15
15.12.2025 15:05:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.11.2025 9:03:29
ConvaTec Grp Rg (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
2,66 -4,58 -0,12 26 600
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.12.2025
Popis společnosti

Business Summary: Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
Financial Summary: BRIEF: For the six months ended 30 June 2025, ConvaTec Group PLC revenues increased 6% to $1.18B. Net income increased 33% to $104.8M. Revenues reflect Infusion Devices segment increase of 14% to $227M, Continence & Critical Care segment increase of 7% to $259.4M, Northern America segment increase of 6% to $657M, Europe segment increase of 6% to $346.6M. Net income benefited from Interest expense on borrowings decrease of 18% to $31.3M (expense).



  • Poslední aktualizace: 15.12.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorAnn Fox48
Chief Financial Officer, Executive Vice PresidentGuy Sirkes3931.03.2020
Chief Operating Officer, Executive Vice PresidentDavid Crombie51
Executive Vice President, General Counsel, Company SecretaryTheodore Moore47